[go: up one dir, main page]

SE9003978D0 - Dna expressionssystem baserade paa ett virus replikon - Google Patents

Dna expressionssystem baserade paa ett virus replikon

Info

Publication number
SE9003978D0
SE9003978D0 SE9003978A SE9003978A SE9003978D0 SE 9003978 D0 SE9003978 D0 SE 9003978D0 SE 9003978 A SE9003978 A SE 9003978A SE 9003978 A SE9003978 A SE 9003978A SE 9003978 D0 SE9003978 D0 SE 9003978D0
Authority
SE
Sweden
Prior art keywords
system based
expression system
virus replication
dna expression
recombinant
Prior art date
Application number
SE9003978A
Other languages
English (en)
Swedish (sv)
Inventor
Henrik Garoff
Peter Liljestroem
Original Assignee
Henrik Garoff
Peter Liljestroem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20381182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9003978(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Henrik Garoff, Peter Liljestroem filed Critical Henrik Garoff
Priority to SE9003978A priority Critical patent/SE9003978D0/xx
Publication of SE9003978D0 publication Critical patent/SE9003978D0/xx
Priority to AU90787/91A priority patent/AU656545B2/en
Priority to PCT/SE1991/000855 priority patent/WO1992010578A1/fr
Priority to ES92900560T priority patent/ES2195998T3/es
Priority to CA002614365A priority patent/CA2614365A1/fr
Priority to CA002098292A priority patent/CA2098292A1/fr
Priority to DK92900560T priority patent/DK0561890T3/da
Priority to JP50179192A priority patent/JP3435511B2/ja
Priority to AT92900560T priority patent/ATE236261T1/de
Priority to EP92900560A priority patent/EP0561890B1/fr
Priority to DE69133228T priority patent/DE69133228T2/de
Priority to US07/920,281 priority patent/US5739026A/en
Priority to FI932678A priority patent/FI932678L/fi
Priority to US08/466,277 priority patent/US6190666B1/en
Priority to US09/688,842 priority patent/US6770283B1/en
Priority to US09/901,106 priority patent/US20020151067A1/en
Priority to JP2002237915A priority patent/JP4018479B2/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SE9003978A 1990-12-13 1990-12-13 Dna expressionssystem baserade paa ett virus replikon SE9003978D0 (sv)

Priority Applications (17)

Application Number Priority Date Filing Date Title
SE9003978A SE9003978D0 (sv) 1990-12-13 1990-12-13 Dna expressionssystem baserade paa ett virus replikon
DE69133228T DE69133228T2 (de) 1990-12-13 1991-12-12 Dna-expressionssysteme basierend auf alphaviren
US07/920,281 US5739026A (en) 1990-12-13 1991-12-12 DNA expression systems based on alphaviruses
JP50179192A JP3435511B2 (ja) 1990-12-13 1991-12-12 Ｄｎａ発現系
AT92900560T ATE236261T1 (de) 1990-12-13 1991-12-12 Dna-expressionssysteme basierend auf alphaviren
ES92900560T ES2195998T3 (es) 1990-12-13 1991-12-12 Sistemas de expresion de dna basados en alfavirus.
CA002614365A CA2614365A1 (fr) 1990-12-13 1991-12-12 Systemes d'expression de l'adn fonde sur les alphavirus
CA002098292A CA2098292A1 (fr) 1990-12-13 1991-12-12 Systemes d'expression de l'adn fonde sur les alphavirus
DK92900560T DK0561890T3 (da) 1990-12-13 1991-12-12 DNA ekspressionssystemer baseret på alphavira
AU90787/91A AU656545B2 (en) 1990-12-13 1991-12-12 DNA expression systems based on alphaviruses
PCT/SE1991/000855 WO1992010578A1 (fr) 1990-12-13 1991-12-12 Systemes d'expression de l'adn bases sur les alphavirus
EP92900560A EP0561890B1 (fr) 1990-12-13 1991-12-12 Systemes d'expression de l'adn bases sur les alphavirus
FI932678A FI932678L (fi) 1990-12-13 1993-06-11 Pao alfavirus baserande dna expressionssystem
US08/466,277 US6190666B1 (en) 1990-12-13 1995-06-06 DNA expression systems based on alphaviruses
US09/688,842 US6770283B1 (en) 1990-12-13 2000-10-17 DNA expression systems based on alphaviruses
US09/901,106 US20020151067A1 (en) 1990-12-13 2001-07-10 DNA expression systems based on alphaviruses
JP2002237915A JP4018479B2 (ja) 1990-12-13 2002-08-19 Ｄｎａ発現系

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9003978A SE9003978D0 (sv) 1990-12-13 1990-12-13 Dna expressionssystem baserade paa ett virus replikon

Publications (1)

Publication Number Publication Date
SE9003978D0 true SE9003978D0 (sv) 1990-12-13

Family

ID=20381182

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9003978A SE9003978D0 (sv) 1990-12-13 1990-12-13 Dna expressionssystem baserade paa ett virus replikon

Country Status (12)

Country Link
US (3) US5739026A (fr)
EP (1) EP0561890B1 (fr)
JP (2) JP3435511B2 (fr)
AT (1) ATE236261T1 (fr)
AU (1) AU656545B2 (fr)
CA (2) CA2614365A1 (fr)
DE (1) DE69133228T2 (fr)
DK (1) DK0561890T3 (fr)
ES (1) ES2195998T3 (fr)
FI (1) FI932678L (fr)
SE (1) SE9003978D0 (fr)
WO (1) WO1992010578A1 (fr)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770283B1 (en) * 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
DK0814154T3 (da) * 1993-09-15 2009-08-31 Novartis Vaccines & Diagnostic Rekombinante alfavirusvektorer
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) * 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
DE19512142A1 (de) * 1995-03-31 1996-10-02 Immuno Ag Infektiöser cDNA-Klon des Tick-Borne Enzephalitis (TBE)-Virus, davon abgeleiteter rekombinanter Impfstoff und Herstellung desselben sowie ein pharmazeutisches Produkt, das eine replizierbare Nukleinsäure enthält
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5639650A (en) * 1995-05-23 1997-06-17 The University Of North Carolina At Chapel Hill cDNA clone for South African Arbovirus No. 86
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6465634B1 (en) 1996-04-05 2002-10-15 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5677124A (en) * 1996-07-03 1997-10-14 Ambion, Inc. Ribonuclease resistant viral RNA standards
US5939262A (en) * 1996-07-03 1999-08-17 Ambion, Inc. Ribonuclease resistant RNA preparation and utilization
US6489167B1 (en) 1996-09-25 2002-12-03 The Government Of The United States As Represented By The Secretary Of The Department Of Human Services Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic Togavirus vectors
EP0932693A1 (fr) * 1996-10-10 1999-08-04 Henrik Garoff Vecteurs alphavirus et retrovirus
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6432699B1 (en) * 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
EP2386629A1 (fr) 1997-10-14 2011-11-16 Darwin Molecular Corporation Mutants de kinase de thymidine et protéines de fusion ayant de la kinase de thymidine et activités de kinase de guanylate
BR9813930A (pt) 1997-11-06 2006-12-19 Chiron Spa antìgeno neisserial
US6475780B1 (en) 1997-11-14 2002-11-05 Aventis Pasteur Limited Alphavirus vectors for paramyxovirus vaccines
WO1999036544A2 (fr) 1998-01-14 1999-07-22 Chiron S.P.A. Antigenes du $i(neisseria meningitidis)
EP1069908B1 (fr) 1998-04-08 2010-02-10 The University of North Carolina at Chapel Hill Vaccin contre le cancer comprenant des particules de replicon d'alphavirus
US6844188B1 (en) 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
CN101293920B (zh) 1998-05-01 2012-07-18 诺华疫苗和诊断公司 脑膜炎奈瑟球菌抗原和组合物
US6719980B1 (en) * 1998-05-08 2004-04-13 Akzo Nobel Nv Structural proteins of fish pancreatic disease virus and uses thereof
WO2000022130A2 (fr) 1998-10-15 2000-04-20 Chiron Corporation Genes regules dans les cellules du cancer du sein metastatique et du cancer du colon
CN100534529C (zh) * 1998-11-30 2009-09-02 希托斯生物技术股份公司 抗原的有序分子呈递，制备及使用的方法
ATE519840T1 (de) 1998-12-16 2011-08-15 Novartis Vaccines & Diagnostic Menschliche cyclin-abhängige kinase (hpnqalre)
AU4366000A (en) 1999-04-14 2000-11-14 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
JP2003518363A (ja) 1999-04-30 2003-06-10 カイロン エセ．ピー．アー． 保存されたナイセリア抗原
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US6297013B1 (en) 1999-06-24 2001-10-02 Dnab Diagnostics Inc. Compositions and methods for determining the activity of DNA-binding proteins and of initiation of transcription
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
WO2001030847A1 (fr) 1999-10-22 2001-05-03 Aventis Pasteur Limited Molecule gp100 modifiee et ses applications
AU784281B2 (en) 1999-10-26 2006-03-02 International Aids Vaccine Initiative Invasive bacterial vectors for expressing alphavirus replicons
DK1801219T3 (en) 1999-10-29 2015-12-07 Glaxosmithkline Biolog Sa Neisseriale antigenic peptides.
PT1232264E (pt) 1999-11-18 2009-11-26 Novartis Vaccines & Diagnostic Gene fgf-21 humano e produtos da expressão do gene
ES2588917T3 (es) 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
JP2003531583A (ja) 2000-03-08 2003-10-28 カイロン コーポレイション ヒトｆｇｆ−２３遺伝子および遺伝子発現産物
CA2407897A1 (fr) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Jeu ordonne d'antigenes moleculaires
PT1282702E (pt) 2000-05-10 2007-02-28 Ludwig Inst Cancer Res Polipéptidos imunogénicos codificados por minigenes mage e suas utilizações
DK1285080T3 (da) * 2000-05-31 2008-12-01 Novartis Vaccines & Diagnostic Fremgangsmåde til oprensning af alphavirusreplikonpartikler
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
WO2002020721A2 (fr) 2000-09-07 2002-03-14 University Of North Carolina At Chapel Hill Vecteurs derives de l'arbovirus sud-africain numero.86
AU2002214127B2 (en) 2000-10-27 2007-06-07 J. Craig Venter Institute, Inc. Nucleic acids and proteins from streptococcus groups A and B
AU2002227153B2 (en) 2000-12-08 2008-01-24 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) * 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
CN1520303B (zh) * 2001-03-27 2013-04-24 纽约大学 利用基于α病毒且靶向高亲和性层粘连蛋白受体的载体进行肿瘤治疗
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2002081641A2 (fr) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 et utilisations diagnostique et therapeutique de ce gene
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
ES2340499T3 (es) 2001-06-05 2010-06-04 Curevac Gmbh Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado.
ATE437222T1 (de) 2001-09-06 2009-08-15 Alphavax Inc Alphavirus replikon-vektorsysteme
BR0213117A (pt) 2001-10-05 2004-09-21 Cytos Biotechnology Ag Conjugados peptìdeo angiotensina-veìculo e seus usos
US7115266B2 (en) * 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
NZ546711A (en) 2001-12-12 2008-06-30 Chiron Srl Immunisation against chlamydia trachomatis
US7877273B2 (en) * 2002-01-08 2011-01-25 Fredric David Abramson System and method for evaluating and providing nutrigenomic data, information and advice
US20030219459A1 (en) * 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
IL163988A0 (en) 2002-03-15 2005-12-18 Wyeth Corp Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
AU2003223527B2 (en) 2002-04-09 2009-01-15 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
PL375306A1 (en) * 2002-06-20 2005-11-28 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
EP1532167B1 (fr) * 2002-07-17 2012-01-25 Cytos Biotechnology AG Reseaux d'antigenes moleculaires utilisant une pseudoparticule virale derivee de la proteine d'enveloppe virale ap205
AU2003250106B2 (en) * 2002-07-18 2009-11-26 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
CA2492930C (fr) 2002-07-19 2013-01-08 Cytos Biotechnology Ag Matrices d'antigenes amyloides beta1-6
JP2006503914A (ja) 2002-10-21 2006-02-02 エムジーアイ ファーマ バイオロジックス インコーポレイテッド ヒトパピローマウイルス媒介性疾患を治療するための組成物および方法
ATE466875T1 (de) 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
BR122019005271B1 (pt) 2002-12-13 2020-10-13 Alphavax, Inc. método para a preparação de partículas de replicon de alfavírus (arps)
JP4991108B2 (ja) 2002-12-13 2012-08-01 アルファバックス，インコーポレイティド 多抗原性アルファウイルス・レプリコン粒子及び方法
WO2004063342A2 (fr) * 2003-01-09 2004-07-29 Invitrogen Corporation Liberation et activation de cellules de complexes de polypeptides et d'acides nucleiques
DK1608762T3 (da) * 2003-03-20 2014-04-07 Alphavax Inc Forbedrede alphavirusreplikoner og hjælperkonstrukter
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US20070087331A1 (en) * 2003-05-15 2007-04-19 Cytos Biotechnology Ag Selection of b cells with specificity if interest: method of preparation and use
EP1651666B1 (fr) * 2003-07-11 2009-05-27 Alphavax, Inc. Vaccins contre cytomegalovirus a base d alphavirus
US7910093B2 (en) 2003-08-19 2011-03-22 New York University Method for detecting cancer cells and monitoring cancer therapy
DE602004032365D1 (de) * 2003-10-08 2011-06-01 Sanofi Pasteur Inc Modifizierter cea/b7-vektor
ZA200604663B (en) * 2004-01-20 2008-02-27 Cytos Biotechnology Ag Particle-induced ghrelin immune response
KR20120126130A (ko) 2004-03-29 2012-11-20 가르파마 컴퍼니 리미티드 신규 갈렉틴 9 개변체 단백질 및 그 용도
ATE420965T1 (de) 2004-05-18 2009-01-15 Alphavax Inc Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
EP1750761A1 (fr) * 2004-06-02 2007-02-14 Cytos Biotechnology AG Utilisations medicales de conjugues porteurs de peptides du tnf non humains
WO2005122675A2 (fr) * 2004-06-21 2005-12-29 Quattromed As Site de reconnaissance optimisee de la protease non structurelle d'alphavirus pour elimination d'etiquette et traitement specifique de proteines de recombinaison
CA2572921C (fr) 2004-07-09 2017-01-03 The University Of North Carolina At Chapel Hill Adjuvants viraux de l'encephalite equine du venezuela a defaut de propagation et competents pour la replication
US7998733B2 (en) 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
AU2006302794B2 (en) * 2005-02-15 2011-08-04 Children's Hospital, Inc. New live virus vaccines
EP3153525A1 (fr) 2005-03-23 2017-04-12 Genmab A/S Anticorps dirigés contre cd38 pour le traitement du myélome multiple
US7303898B2 (en) * 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
EP2054431B1 (fr) 2006-06-09 2011-08-31 Novartis AG Conformères d'adhésines bactériennes
WO2008085557A2 (fr) 2006-09-12 2008-07-17 Alphavax, Inc. Particules de réplicon d'alphavirus utilisées en tant qu'adjuvants immunologiques
WO2008033966A2 (fr) 2006-09-12 2008-03-20 Alphavax, Inc. Particules de réplicon d'alphavirus correspondant à des antigènes de protéines utilisées en qualité d'adjuvants immunologiques
NZ576563A (en) * 2006-11-03 2012-09-28 Alphavax Inc Alphavirus and alphavirus replicon particle formulations and methods
US8673859B2 (en) 2007-03-20 2014-03-18 New York University GM-CSF cosmeceutical compositions and methods of use thereof
CA2689588C (fr) 2007-06-21 2016-08-23 Alphavax, Inc. Cassettes sans promoteur pour l'expression de proteines structurales d'alphavirus
PL2222697T3 (pl) 2007-11-01 2013-05-31 Astellas Pharma Inc Immunosupresyjne polipeptydy i kwasy nukleinowe
EP2370584B1 (fr) 2008-12-01 2014-11-05 Alphavax, Inc. Utilisation de micro-ARN pour le contrôle d'acides nucléiques d'aide de virus
EP2416662B1 (fr) 2009-04-08 2015-03-25 Alphavax, Inc. Particules de réplicon d'alphavirus exprimant trp2
WO2011038063A1 (fr) 2009-09-28 2011-03-31 The Trustees Of The University Of Pennsylvania Procédé pour diagnostiquer et traiter la cystite interstitielle
EE05711B1 (et) 2009-10-07 2014-04-15 Tartu Ülikool Meetod ja kompositsioon konditsionaalselt letaalsete viirusmutantide loomiseks ja eukarootse raku elulisuse k?rvaldamiseks
WO2011064437A2 (fr) 2009-11-26 2011-06-03 Proyecto De Biomedicina Cima, S.L. Vecteurs viraux et procédés utiles dans la préparation de gdnf
CA2793959C (fr) 2010-03-25 2019-06-04 Oregon Health & Science University Glycoproteines du cmv et vecteurs recombines
US9198975B2 (en) 2010-12-01 2015-12-01 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
EP2668201A2 (fr) 2011-01-28 2013-12-04 Sanofi Pasteur SA Compositions immunogeniques comprenant des dérivés du polypeptide gp41 de hiv
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
WO2014140938A2 (fr) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Méthodes immunologiques
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (fr) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Trimères de glycoprotéines d'enveloppe du vih -1 soluble
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (fr) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
WO2017184456A1 (fr) * 2016-04-18 2017-10-26 Rima Mcleod Vaccins contre le toxoplasma gondii et leur utilisation
ES2925083T3 (es) * 2017-02-27 2022-10-13 Translate Bio Inc Métodos de purificación de ARN mensajero
MX2022001468A (es) 2019-08-09 2022-07-19 Nutcracker Therapeutics Inc Metodos y aparatos de fabricación para remover material de una composición terapeutica.
WO2024149832A1 (fr) 2023-01-12 2024-07-18 Bavarian Nordic A/S Sarna (vrp) modifié recombinant pour vaccin contre le cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1288073C (fr) * 1985-03-07 1991-08-27 Paul G. Ahlquist Vecteur de transformation de l'arn
WO1989012095A1 (fr) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. Procede d'evaluation de vaccins recombinants contre le virus de l'immunodeficience
US4943628A (en) * 1988-06-13 1990-07-24 Ortho Pharmaceutical Corporation HIV peptide-inducted T cell stimulation
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems

Also Published As

Publication number Publication date
CA2098292A1 (fr) 1992-06-14
DK0561890T3 (da) 2003-07-21
DE69133228T2 (de) 2003-10-30
DE69133228D1 (de) 2003-05-08
FI932678L (fi) 1993-07-27
CA2614365A1 (fr) 1992-06-25
ATE236261T1 (de) 2003-04-15
JP4018479B2 (ja) 2007-12-05
WO1992010578A1 (fr) 1992-06-25
FI932678A0 (fi) 1993-06-11
JPH06504198A (ja) 1994-05-19
EP0561890A1 (fr) 1993-09-29
EP0561890B1 (fr) 2003-04-02
AU9078791A (en) 1992-07-08
AU656545B2 (en) 1995-02-09
US5739026A (en) 1998-04-14
US6190666B1 (en) 2001-02-20
US20020151067A1 (en) 2002-10-17
JP3435511B2 (ja) 2003-08-11
ES2195998T3 (es) 2003-12-16
JP2003159085A (ja) 2003-06-03

Similar Documents

Publication Publication Date Title
SE9003978D0 (sv) Dna expressionssystem baserade paa ett virus replikon
BR7908410A (pt) Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
DE3852221D1 (de) Tierische Zelle mit darin eingeführtem antigenem Protein.
ATE188740T1 (de) Viruspartikel mit veraendertem wirtspektrum
ES8500322A1 (es) Un metodo de modificar un virus para conferirle una nueva funcion biologica.
DK163683D0 (da) Fremstilling af funktionelle humane urokinaseproteiner, dna-sekvens, der koder for et protein omfattende den enzymatiske del af human urokinase, replicerbart udtrykkelsesmedium, der kan udtrykkedna-sekvensen og mikroorganisme eller cellekultur transformeret med mediet
DK2295065T3 (da) Modificeret varmechockprotein-antigenpeptidkompleks
ATE325882T1 (de) Polypeptide, die mit alfalfamosaikviralen oder ilarviralen kapsiden fusioniert sind
DK0757717T3 (da) Papillomavirusvacciner
DE69837708D1 (de) Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektion
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
KR970705408A (ko) 헤모필루스 부착 및 침투 단백질(haemophilus adherence and penetration proteins)
ATE101200T1 (de) Impfstoffe gegen menschliche respiratorische viren.
DE68923006D1 (de) Fusionsproteine der untereinheit b von choleratoxin und eines heterologen antigens und dafür kodierende rekombinante nukleinsäure.
EP0236977A3 (fr) Vaccins contre la diarrhée bovine virale et le choléra porcin
FR2635532B1 (fr) Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
FI953371A0 (fi) TBE-virusinfektiota vastaan tähtäävään immunisointiin tarkoitetut parannetut rokotteet sekä menetelmä niiden valmistamiseksi
BR0010222A (pt) Vetores de expressão viral
EP0676413A3 (fr) Protéine liant l'interféron alpha/bêta, sa production et son application.
HK1052368A1 (zh) 具有源於肝炎e病毒orf2的n末端部分及一抗原多肽加工的編碼成份的核酸結構
BR9508645A (pt) Vacina da peritonite infecciosa felina
WO2002083896A3 (fr) Virus recombinant segmente a polarite negative contenant un segment d'arnv bicistronique avec duplication de sa sequence laterale 3' non codante, et vaccins et compositions therapeutiques le contenant
SE8700466D0 (sv) Vaccines against melanoma
KR830010193A (ko) 바실러스 클로닝 매개체, 재결합 dna분자 그것들과 함께 변형된 간균 숙주 그리고 이종(異知) dna배열의 표현 방법과 그것으로 이루어진 폴리펩타이드의 생성방법
ATE105335T1 (de) Traegergebundene rekombinante proteine, verfahren zur herstellung und verwendung als immunogene und vakzine.